A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells.
A new recombinant adenovirus carrying a wild-type p53 gene (AxCAp53) was developed and the combination effect of p53 gene transfer and cis-diamminedichloroplatinum (II) (CDDP) was examined in an ovarian cancer cell line, SK-OV-3, with deletion of the p53 gene. AxCAp53 showed a high efficiency of gene transduction and increased sensitivity to CDDP in the SK-OV-3 cells. It was found that the sensitivity of the cells to CDDP correlated with the amount of infectious units of virus per cell of AxCAp53 which correlated with p53 protein expression. The results suggest that the combination of CDDP and AxCAp53 may be a potential strategy for the therapy of CDDP-resistant ovarian cancer.
Kanamori
Y
Y
Department of Obstetrics and Gynaecology, Tottori University School of Medicine, Yonago, Japan.
Kigawa
J
J
Minagawa
Y
Y
Irie
T
T
Oishi
T
T
Shimada
M
M
Takahashi
M
M
Nakamura
T
T
Sato
K
K
Terakawa
N
N
D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D000260:Adenoviruses, Human; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D018014:Gene Transfer Techniques; D016158:Genes, p53; D006801:Humans; D008297:Male; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; C034697:transplatin; D002945:Cisplatin